Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · INN directory

Pharmaceutical Drugs

Regulatory status, brand names, and pipeline context for BD, medical affairs, and competitive intelligence teams.

Drugs indexed 4,797
Companies 1,769
Pipeline programs 20,548

Quick answer

NovaPharmaNews tracks 4,797 pharmaceutical drugs by INN (International Nonproprietary Name), with US FDA approval status, brand names, originators, routes of administration, and links to pipeline programs and patents. Search by generic name or browse A–Z for competitive intelligence and medical affairs reference.

Recently updated

FDA-approved

Showing page 100 of 200 · By data quality, then INN

  1. ritodrine hydrochloride

    RITODRINE HYDROCHLORIDE

    INJECTION FDA: approved

  2. rituximab

    RIXIMYO Pfizer Australia Pty Ltd

    SUBCUTANEOUS FDA: approved · EMA: approved · TGA: approved · PMDA: approved · NMPA: clinical trials

    L01FA01

  3. rituximab-abbs

    TRUXIMA

    INJECTION FDA: approved

  4. rituximab-arrx

    RIABNI

    INJECTION FDA: approved

  5. rituximab-pvvr

    RUXIENCE

    INJECTION FDA: approved

  6. rivastigmine tartrate

    RIVASTIGMINE TARTRATE

    ORAL FDA: approved

  7. rofecoxib

    VIOXX

    ORAL FDA: approved

  8. rolapitant hydrochloride

    VARUBI

    ORAL FDA: approved

  9. romiplostim

    NPLATE Amgen

    SUBCUTANEOUS FDA: approved · EMA: approved · TGA: approved · PMDA: approved · NMPA: clinical trials

    B02BX04

  10. romosozumab-aqqg

    EVENITY

    INJECTION FDA: approved

  11. rose bengal sodium i-131

    SODIUM ROSE BENGAL I 131

    INJECTION FDA: approved

  12. rosiglitazone maleate

    ROSIGLITAZONE MALEATE

    ORAL FDA: approved

  13. rosuvastatin zinc

    ROSUVASTATIN ZINC

    ORAL FDA: approved

  14. rotigotine

    NEUPRO

    TRANSDERMAL FDA: approved · EMA: approved · TGA: approved · NMPA: clinical trials

    N04BC09

  15. rozanolixizumab-noli

    RYSTIGGO

    SUBCUTANEOUS FDA: approved

  16. rubidium chloride rb-82

    RUBY-FILL

    INJECTION FDA: approved

  17. rucaparib camsylate

    RUBRACA

    ORAL FDA: approved

  18. rufinamide

    INOVELON

    ORAL FDA: approved · EMA: approved

    N03AF03

  19. ruxolitinib

    JAKAVI Novartis Pharmaceuticals

    ORAL FDA: approved · EMA: approved · TGA: approved · NMPA: clinical trials

    D11AH

  20. ruxolitinib phosphate

    JAKAFI XR

    TOPICAL FDA: approved

  21. sacituzumab govitecan-hziy

    TRODELVY

    INJECTION FDA: approved

  22. sacrosidase

    SUCRAID

    ORAL FDA: approved

  23. sacubitril

    ENTRESTO

    ORAL FDA: approved · EMA: approved

    C09DX04

  24. safflower oil

    LIPOSYN 10%

    INJECTION FDA: approved

Frequently asked questions

What is the NovaPharmaNews drugs directory?

It is a searchable index of 4,797 pharmaceutical active ingredients and their marketed profiles — INN, brand names, US regulatory status, manufacturers, and cross-links to clinical pipeline and patent records.

Where does drug approval data come from?

Profiles combine FDA Drugs@FDA and Orange Book references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence. This directory is for professional reference, not medical advice.

How do I find a drug by brand name?

Use the search box on this page — it matches both INN (generic name) and slug. Brand names appear on each drug row and on the full drug profile page, with links to the originator company when available.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.